Prosecution Insights
Last updated: April 19, 2026

Examiner: TRAN, SUSAN T

Tech Center 1600 • Art Units: 1615 1618

This examiner grants 63% of resolved cases

Performance Statistics

62.6%
Allow Rate
+2.6% vs TC avg
1061
Total Applications
+35.9%
Interview Lift
1227
Avg Prosecution Days
Based on 1009 resolved cases, 2023–2026

Rejection Statute Breakdown

0.3%
§101 Eligibility
22.7%
§102 Novelty
39.1%
§103 Obviousness
21.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19221432 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Final Rejection Veradermics, Incorporated
19308925 AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF Final Rejection Deciphera Pharmaceuticals, LLC
18042930 NICLOSAMIDE PARTICLES AND USES THEREOF Final Rejection CRITITECH, INC.
19270315 PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE Final Rejection ANTECIP BIOVENTURES II LLC
18008793 ANATABINE POWDER COMPOSITIONS Non-Final OA PHILIP MORRIS PRODUCTS S.A.
19190529 IMMEDIATE RELEASE MULTILAYER TABLET Final Rejection Alkermes Pharma Ireland Limited
19171169 METHODS OF USING RADIPRODIL IN THE TREATMENT OF DISORDERS Final Rejection GRIN Therapeutics, Inc.
18413822 PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF Final Rejection Boehringer Ingelheim International GmbH
17991697 OSMOTIC DRUG DELIVERY SYSTEM Non-Final OA Supernus Pharmaceuticals, Inc.
18057119 SOLID PHARMACEUTICAL TABLET Final Rejection Genexa Inc.
18284981 METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS Non-Final OA INVENTAGE LAB INC.
18212671 PROCESS FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS HAVING A TESTOSTERONE COMPOUND PRESENT IN AN OUTER LAYER OR PART, AS WELL AS SUCH DRUG DELIVERY SYSTEMS Non-Final OA EB IP Hybritabs B.V.
18015192 SWELLABLE ORAL PHARMACEUTICAL COMPOSITIONS Non-Final OA Adare Pharmaceuticals, Inc.
18010245 FORMULATION COMPRISING DAPRODUSTAT Non-Final OA GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
18532735 COMPOSITIONS FOR PRE-SURGICAL NUTRITIONAL SUPPLEMENTS Non-Final OA TM Nutrition LLC
18019856 SOLID ORAL COMPOSITION COMPRISING CARBAMATE COMPOUND, AND PREPARATION METHOD THEREFOR Final Rejection SK BIOPHARMACEUTICALS CO., LTD.
18559440 LOSARTAN-CONTAINING MICRO TABLET FOR PEDIATRIC APPLICATIONS Non-Final OA Midas Pharma GmbH
18288382 SLEEP-REGULATING TABLET ALLOWING RELEASE BY STAGES AND PREPARATION METHOD THEREOF Non-Final OA OVERSEAS PHARMACEUTICALS, LTD.
18001635 Dispersible Tablet Formulations Comprising Dolutegravir Final Rejection ViiV Healthcare Company
18001634 Formulations Final Rejection ViiV Healthcare Company
18276464 A PROBIOTIC GRANULE HAVING A UNIFIED STABILIZING COATING AND A METHOD FOR THE PRODUCTION THEREOF Non-Final OA AMD PHARMA LTD
18359973 FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS Non-Final OA XSPRAY PHARMA AB
18064383 FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS Final Rejection XSPRAY PHARMA AB
18273732 STABLE EMULSIONS AND METHODS Non-Final OA Hemp Hunter Labs Inc.
18043176 PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB Final Rejection Synthon B.V.
18207099 COMPOSITIONS AND METHODS FOR TREATING DISEASES OR DISORDERS USING EXTENDED RELEASE NITRIC OXIDE RELEASING SOLUTIONS Non-Final OA SaNOtize Research and Development Corp.
18127214 OSMOTIC DRUG DELIVERY IMPLANTS Non-Final OA LYRA THERAPEUTICS, INC.
17911040 TABLET, MEDICINE, METHODS FOR PRODUCING THESE, AND KIT Non-Final OA Eisai R&D Management Co., Ltd.
18303789 N-PALMITOYLETHANOLAMIDE AND MELATONIN FOR USE IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND OTHER NEUROBEHAVIORAL DISORDERS SIMILARLY ACCOMPANIED BY RESTLESSNESS, IRRITABILITY, SLEEP DISORDERS, AND POTENTIALLY STEREOTYPIES Final Rejection EPITECH GROUP S.P.A.
18040383 LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS Non-Final OA Captor Therapeutics S.A.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month